PD-1及其配体PD-L1与乳腺癌的研究进展  

Research progress of PD-1 and its ligand PD-L1 in breast cancer

作　　者：张艳珍 胡蝶 郑瑞 章健 浦春[1] ZHANG Yanzhen;HU Die;ZHENG Rui;ZHANG Jian;PU Chun(Laboratory Examination,Yijishan Hospital,Wannan Medical College,Wuhu 241001,China)

机构地区：[1]皖南医学院弋矶山医院检验科,安徽芜湖241001

出　　处：《沈阳医学院学报》2021年第2期177-181,共5页Journal of Shenyang Medical College

基　　金：安徽省教育厅自然科学研究重点项目(No.kj2016A722)。

摘　　要：乳腺癌近期研究显示,一些侵袭性三阴性乳腺癌具有免疫原性,对化疗有抵抗力,预后不良。程序性死亡因子1(programmed death 1,PD-1)及程序性死亡因子配体1 (programmed death-ligand 1,PD-L1)近年来已成为肿瘤免疫治疗的研究热点。免疫治疗在恶性黑色素瘤、肺癌等肿瘤中疗效满意,由于乳腺癌的"弱免疫原性",免疫治疗效果不佳。现在乳腺癌的免疫治疗研究越来越多,发现免疫治疗在乳腺癌中也有一定的疗效。本文将阐述PD-1/PD-L1在肿瘤微环境相关机制,免疫检查点阻断,免疫治疗方面的前景与挑战以及PD-L1表达的实验室检测方法的探讨及相关研究进展。Recent studies have shown that some invasive triple negative breast cancer(TNBC)have immunogenicity,chemotherapy resistance and poor prognosis.Programmed death 1(PD1)and programmed death-ligand 1(PD-L1)have become research hotspots in tumor immunotherapy in recent years.Immunotherapy is effective in malignant melanoma,lung cancer and other tumors.Because of the“weak immunogenicity”of breast cancer,immunotherapy may be not effective.However,more and more studies on immunotherapy of breast cancer have found that immunotherapy has a certain effect in breast cancer.This paper reviews the mechanism of PD-1/PD-L1 in tumor microenvironment,the blockade of immunocheckpoint,the prospect and challenge of immunotherapy,and the laboratory detection methods of PD-L1 expression.

关 键 词：PD-1 PD-L1 乳腺癌 免疫疗法 PD-L1检测 

分 类 号：R736.8[医药卫生—肿瘤]